The long-term safety evidence gap for emerging nonsteroidal topical therapies in pediatric atopic dermatitis
DOI:
https://doi.org/10.5281/zenodo.23807703Keywords:
Atopic Dermatitis. Child. Drug Safety. Drug Therapy. Pharmacovigilance.Abstract
Pediatric atopic dermatitis often requires repeated topical treatment, making it essential to distinguish the favorable tolerability observed in clinical trials from safety established after prolonged cumulative exposure. This review critically analyzed safety evidence for crisaborole, roflumilast, ruxolitinib, tapinarof, delgocitinib, and difamilast in children and infants. A narrative review was conducted using SciSpace searches and supplementary verification of published studies, clinical guidelines, and regulatory documents, updated through October 2026. Randomized trials, open-label extensions, pharmacokinetic investigations, and literature syntheses were considered. Available evidence includes 48- to 60-week follow-up, maximum-use investigations, and infant cohorts, although some findings come from small samples or mixed-age populations (Bissonnette et al., 2025; Igarashi et al., 2026; Saeki et al., 2026). A network meta-analysis of 15 clinical trials involving 3,994 pediatric participants indicated generally favorable short-term tolerability, while direct comparisons between active agents remained scarce (Yang et al., 2026). Favorable results over approximately one year cannot exclude rare events, long-latency effects, or risks associated with exposure over several years. Longitudinal pediatric studies and structured pharmacovigilance are needed to clarify these unresolved safety questions (Davis et al., 2026; Chokshi et al., 2026).
References
BISSONNETTE et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. Journal of the American Academy of Dermatology, 93(3), 707–714, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1391.
CHOKSHI et al. Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology, 2026. DOI: https://doi.org/10.1111/pde.70298.
DAVIS et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 95(1), 121.e1–121.e26, 2026. DOI: https://doi.org/10.1016/j.jaad.2026.02.113.
EICHENFIELD et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 77(4), 641–649.e5, 2017. DOI: https://doi.org/10.1016/j.jaad.2017.06.010.
EICHENFIELD et al. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study. American Journal of Clinical Dermatology, 24(4), 623–635, 2023. DOI: https://doi.org/10.1007/s40257-023-00780-w.
EICHENFIELD et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. Journal of the American Academy of Dermatology, 93(3), 689–698, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1385.
EICHENFIELD et al. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). Pediatric Dermatology, 43(3), 642–649, 2026. DOI: https://doi.org/10.1111/pde.70177.
GARG et al. Topical Janus Kinase Inhibitors for Atopic Dermatitis in Children Under 12 Years: A Systematic Review. The Journal of Pediatric Academy, 2026. DOI: https://doi.org/10.4274/jpea.2026.514.
GILLESPIE et al. Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis. Current Opinion in Pediatrics, 38(4), 382–388, 2026. DOI: https://doi.org/10.1097/MOP.0000000000001580.
IGARASHI et al. Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Artigo 17307, 2026. DOI: https://doi.org/10.3389/jcia.2026.17307.
JOYCE et al. Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study. American Journal of Clinical Dermatology, 27, 841–849, 2026. DOI: https://doi.org/10.1007/s40257-026-01043-0.
NAKAGAWA et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Journal of the American Academy of Dermatology, 2021. DOI: https://doi.org/10.1016/j.jaad.2021.06.014.
NAKAGAWA et al. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergology International, 73(1), 137–142, 2024. DOI: https://doi.org/10.1016/j.alit.2023.04.003.
NATIONAL LIBRARY OF MEDICINE. VTAMA — tapinarof cream: prescribing information (atualização 2025). DailyMed, 2025. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9309d20f-8cd4-4c96-93fa-7f730e83c7ab. Acesso em: 28 out. 2026.
NATIONAL LIBRARY OF MEDICINE. ZORYVE — roflumilast cream: prescribing information (atualização 2026). DailyMed, 2026a. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec1bb0d1-f38a-4080-831a-68791d1d1fdb. Acesso em: 28 out. 2026.
NATIONAL LIBRARY OF MEDICINE. OPZELURA — ruxolitinib cream: prescribing information (atualização de 30 jun. 2026). DailyMed, 2026b. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7. Acesso em: 28 out. 2026.
PAPP et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology, 88(5), 1008–1016, 2023. DOI: https://doi.org/10.1016/j.jaad.2022.09.060.
SAEKI et al. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. British Journal of Dermatology, 186(1), 40–49, 2022. DOI: https://doi.org/10.1111/bjd.20655.
SAEKI et al. A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis. Dermatology and Therapy (Heidelberg), 16(1), 339–352, 2026. DOI: https://doi.org/10.1007/s13555-025-01581-1.
SCHLESSINGER et al. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology, 21(2), 275–284, 2020. DOI: https://doi.org/10.1007/s40257-020-00510-6.
SIEGFRIED et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatrics, 2016. DOI: https://doi.org/10.1186/s12887-016-0607-9.
SILVERBERG et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. Journal of the American Academy of Dermatology, 91(3), 457–465, 2024. DOI: https://doi.org/10.1016/j.jaad.2024.05.023.
SIMPSON et al. Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis, 37(1), 75–83, 2026. DOI: https://doi.org/10.1089/derm.2024.0418.
STEIN GOLD et al. A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 26(2), 275–289, 2025. DOI: https://doi.org/10.1007/s40257-024-00909-5.
YANG et al. Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Immunology, 17, 1906218, 2026. DOI: https://doi.org/10.3389/fimmu.2026.1906218.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Social Issues and Health Sciences (JSIHS)

This work is licensed under a Creative Commons Attribution 4.0 International License.
